Pieris Pharmaceuticals (NASDAQ:PIRS) Upgraded at StockNews.com

StockNews.com upgraded shares of Pieris Pharmaceuticals (NASDAQ:PIRS) from a sell rating to a hold rating in a report published on Monday morning.

Pieris Pharmaceuticals Stock Performance

Shares of NASDAQ PIRS opened at $15.95 on Monday. The business has a 50-day moving average of $16.66 and a 200-day moving average of $13.72. Pieris Pharmaceuticals has a fifty-two week low of $6.20 and a fifty-two week high of $22.32.

Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($2.76) earnings per share for the quarter. Pieris Pharmaceuticals had a negative return on equity of 75.34% and a negative net margin of 39.71%.

Institutional Trading of Pieris Pharmaceuticals

An institutional investor recently bought a new position in Pieris Pharmaceuticals stock. BML Capital Management LLC acquired a new position in shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 42,130 shares of the biotechnology company’s stock, valued at approximately $699,000. Pieris Pharmaceuticals accounts for 0.4% of BML Capital Management LLC’s investment portfolio, making the stock its 21st biggest holding. BML Capital Management LLC owned about 3.19% of Pieris Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.